Amgen (AMGN) Change in Accured Expenses (2009 - 2026)

Amgen's Change in Accured Expenses history runs 18 years deep, the most recent figure standing at -$959.0 million for Q1 2026.

• In Q1 2026, Change in Accured Expenses fell 9.73% year-over-year to -$959.0 million; the TTM figure through Mar 2026 stood at -$241.0 million (down 188.6% YoY), while the FY2025 annual figure was -$156.0 million, down 269.57% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$959.0 million, down from -$76.0 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $1.1 billion in Q4 2023, with the low at -$1.1 billion in Q1 2024.
• The 5-year median for Change in Accured Expenses is -$30.0 million (2025), against an average of $1.6 million.
• The sharpest annual moves came in 2023 and 2024: Change in Accured Expenses surged 401.37% in 2023, then tumbled 358.26% in 2024.
• Amgen's Change in Accured Expenses stood at -$366.0 million in 2022, then soared by 401.37% to $1.1 billion in 2023, then tumbled by 85.13% to $164.0 million in 2024, then slumped by 146.34% to -$76.0 million in 2025, then sank by 1161.84% to -$959.0 million in 2026.
• Business Quant data shows AMGN's Change in Accured Expenses at -$959.0 million in Q1 2026, -$76.0 million in Q4 2025, and -$30.0 million in Q3 2025.